2 multi-bagging growth stocks I’d buy for 2018

It looks like 2018 could be a great year for growth investors. Here are two high-flying stocks for you to check out.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It can be hard plucking up the courage to invest in a stock that has already multi-bagged, but sometimes they just keep going up.

Shares in Clinigen Group (LSE: CLIN) have more than four-bagged over the past five years, as earnings have been growing in double-digits every year. The year to June 2017 brought in a 25% rise, and analysts are predicting 13% this year followed by 19% next.

I was happy to read the company’s first-half trading update on Wednesday, which told us that the first half has been “in line with the board’s expectations.” Revenues are up by around 28%, with gross profit up by about 10% — the latter is, apparently, the board’s preferred measure of top-line growth.

So I was surprised to see the share price down by 3% at the time of writing, to 1,003p. But I guess that’s part of the fickleness of a high-flying growth stock, which can falter when figures fail to beat expectations.

Excellent growth

The highlight was the company’s Commercial Medicines division, which apparently accounts for 49% of gross profit, and which “delivered excellent growth, with all products across the portfolio performing strongly.

Unlicensed Medicines, representing 41% of gross profit, seems to have had a mixed time, but “a significant number of new programmes now starting” are expected to boost performance in the second half.

The Clinical Trial Services business, with 10% of gross profit, saw its performance fall back from last year’s, and that might also have contributed to the morning’s sell-off. But Clinigen says it should do better in the second half.

On current growth forecasts we’re looking at a forward P/E of 21 for June 2018, dropping to 18 on 2019 expectations. Dividends are currently yielding only around 0.5%, but they’re very well covered and strongly progressive.

And even though the share price has already climbed, I’m still seeing an attractive long-term valuation here.

10-bagger

Shares in JD Sports Fashion (LSE: JD) have done even better, 10-bagging in five years. And even after that, with the shares at 390p, we’re still only looking at forward P/E multiples of 13 to 15, which is around the FTSE 100‘s long-term average.

Admittedly there’s not much in the way of dividend cash right now, with yields similar to Clinigen’s 0.5% level. But we’re looking at cover of around 14 times by earnings, and I can see the company morphing into a solid cash cow in future years.

Tuesday’s update which covered the Christmas trading period impressed me, especially when so many other retailers have been feeling the high-street pinch. And instead of falling earnings that some are now predicting, JD has upped its full-year pre-tax profit guidance to £300m, ahead of the market’s £270m-£295m prior consensus.

Online business is expanding too, and I’m becoming more and more convinced that the retail future will belong to companies that combine internet sales with physical stores — the demand for the ability to collect and/or return goods in-store is growing.

Though I don’t pay much attention to share price charts, I am drawn to the fact that JD shares are still significantly below their May 2017 peak of over 450p — I thought the shares were fair value then, and now I reckon I’m seeing a bargain. The year ends 31 January, with results due 17 April.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended Clinigen. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Google office headquarters
Investing Articles

1 reason I like buying S&P 500 shares – and 1 reason I don’t

Will this investor try to improve his potential returns by focusing more on S&P 500 shares instead of British ones?…

Read more »

Young woman holding up three fingers
Investing Articles

3 SIPP mistakes to avoid

Our writer explains a trio of potentially costly errors he tries to avoid making when investing his SIPP, on an…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Here’s how (and why) I’d start buying shares with £25 a week

Our writer uses his investment experience and current approach to explain how he would start buying shares on a limited…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s my 5-step approach to earning passive income of £500 a month

Christopher Ruane explains the handful of steps he uses to target hundreds of pounds in passive income each month.

Read more »

Investing Articles

2 UK shares I’ve been buying this week

From a value perspective, UK shares look attractive. But two in particular have been attracting Stephen Wright’s attention over the…

Read more »

Investing Articles

A lifelong second income for just £10 a week? Here’s how!

With a simple, structured approach to buying blue-chip dividend shares at attractive prices, our writer's building a second income for…

Read more »

Investing Articles

Here’s how I’d use a £20k Stocks and Shares ISA to help build generational wealth

Discover how our writer would aim to turn a £20k Stocks and Shares ISA into a sizeable nest egg by…

Read more »